Oncology, cancer prevention, tumor biology, and immunotherapy relevant to longevity
635 artigos
New research reveals how lung cancer subclones develop distinct immune evasion strategies, complicating immunotherapy response.
Memorial Sloan Kettering-led trials produced 11 new FDA-approved cancer therapies in a single year, spanning multiple tumor types.
New research reveals how corticotroph pituitary tumors develop resistance to temozolomide through clonal selection of high MGMT-expressing cells.
A multinational study of 4,913 patients finds EBRT delivers survival outcomes comparable to surgery and ablation for early hepatocellular carcinoma.
Adding targeted radiation to standard therapy reduced progression by 46% across multiple cancer types in the EXTEND trial.
A randomized trial shows hormone receptor-positive/HER2+ early breast cancer patients had 100% 5-year overall survival with endocrine therapy plus dual HER2 blockade.
Orally bioavailable cyclin A/B RxL inhibitors exploit a cell-cycle vulnerability in small-cell lung cancer and other G1-S-checkpoint-deficient tumors.
MYC protein doesn't just fuel tumor growth — it also repairs DNA damage from chemotherapy, revealing a key resistance mechanism.
NCI-sponsored trial evaluates safety and optimal dosing of immune checkpoint blockade following standard chemoradiation in locally advanced cervical cancer.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
AML stem cells produce BHB via autonomous ketogenesis to block ferroptosis, revealing a targetable metabolic vulnerability in leukemia.
Scientists identify CD300ld as a key mechanism by which tumor-infiltrating neutrophils silence CD8+ T cells, opening a new immunotherapy target.
